Peptide boom exposes evidence gaps as drug development and prescribing markets draw interest

Your call?🐂 Bullish🐻 Bearish

Tirzepatide sales reached nearly $44 billion in the first nine months of 2026. Andreessen Horowitz examines evidence gaps in unapproved peptides and prospects for regulated drugs and prescribing businesses.